BC
MRVI icon

Bridgefront Capital’s Maravai LifeSciences MRVI Stock Holding History

Bridgefront Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,573
Closed -$161K – 500
2023
Q4 		$161K Buy
+24,573
New +$159K 0.12% 314
2023
Q3 		– Sell
-10,089
Closed -$125K – 533
2023
Q2 		$125K Sell
10,089
-6,692
-40% -$90.3K 0.07% 413
2023
Q1 		$235K Buy
+16,781
New +$241K 0.14% 285

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgefront Capital's MRVI Position: Q1 2024 in Review

Bridgefront Capital sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 24,573 shares — an estimated $161K sold.

Bridgefront Capital first reported a position in MRVI in Q1 2023 and held it in 3 quarters. The position peaked at $235K in Q1 2023. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

  • Bridgefront Capital reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Bridgefront Capital sold 24,573 Maravai LifeSciences shares in Q1 2024, an estimated $161K.
  • Bridgefront Capital first reported a position in Maravai LifeSciences in Q1 2023 and held it in 3 quarters.
  • Bridgefront Capital's Maravai LifeSciences position peaked at $235K in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Bridgefront Capital's 13F filing for Q1 2024, filed 15 May 2024.